Published: Jan. 1, 2025
Language: Английский
Biomedicines, Journal Year: 2024, Volume and Issue: 12(8), P. 1758 - 1758
Published: Aug. 5, 2024
Uveal melanoma (UM) is the most common intraocular malignancy in adults. Recent advances highlight role of tumor-derived extracellular vesicles (TEV) and circulating hybrid cells (CHC) UM tumorigenesis. Bridged with liquid biopsies, a novel technology that has shown incredible performance detecting cancer or products derived from tumors bodily fluids, it can significantly impact disease management outcome. The aim this comprehensive literature review to provide summary current knowledge ongoing posterior pathophysiology, diagnosis, treatment. first section manuscript discusses complex intricate TEVs CHCs. second part delves into epidemiology, etiology risk factors, clinical presentation, prognosis UM. Third, diagnostic methods, ensued by tools for early detection UM, such as biopsies artificial intelligence-based technologies, are paramount importance review. fundamental principles, limits, challenges associated these tools, well their potential tracker progression, discussed. Finally, treatment modalities provided, followed an overview preclinical research studies further insights on biomolecular pathway alterations therapeutic targets This thus important resource all healthcare professionals, clinicians, researchers working field ocular oncology.
Language: Английский
Citations
7
Journal of Gastrointestinal Cancer, Journal Year: 2024, Volume and Issue: 55(3), P. 990 - 1003
Published: May 2, 2024
Language: Английский
Citations
6
Annals of Medicine, Journal Year: 2024, Volume and Issue: 56(1)
Published: May 13, 2024
Background Relapse/refractory B-cell acute lymphoblastic leukaemia (r/r B-ALL) represents paediatric cancer with a challenging prognosis. CAR T-cell treatment, considered an advanced remains controversial due to high relapse rates and adverse events. This study assessed the efficacy safety of therapy for r/r B-ALL.
Language: Английский
Citations
6
Viruses, Journal Year: 2023, Volume and Issue: 15(3), P. 789 - 789
Published: March 19, 2023
Chimeric antigen receptor (CAR) technology is having a huge impact in the blood malignancy field and becoming well-established therapy for many types of leukaemia. In recent decades, efforts have been made to demonstrate that CAR-T cells potential as achieve sterilizing cure human immunodeficiency virus (HIV) infection. However, translation this HIV scenario has not easy, challenges appeared along way hinder consolidation putative therapy. Here, we review origin development cells, describe advantages cell comparison with other therapies, major obstacles currently faced regarding application field, specifically, viral escape, infectivity, accessibility hidden reservoirs. Nonetheless, promising results successfully tackling some these issues obtained clinical trials suggest bright future consolidated
Language: Английский
Citations
14
Gene Therapy, Journal Year: 2024, Volume and Issue: 31(7-8), P. 366 - 377
Published: March 14, 2024
Abstract Adoptive cell therapy (ACT), particularly chimeric antigen receptor (CAR)-T therapy, has emerged as a promising approach for targeting and treating rare oncological conditions. The orphan medicinal product designation by the European Union (EU) plays crucial role in promoting development of medicines conditions according to EU Orphan Regulation. This regulatory landscape analysis examines evolution, challenges, clinical outcomes genetically engineered ACT, with focus on CAR-T therapies, based Medicines Agency’s Committee Medicinal Products review applications evaluated maintenance status over 10-year period. In total, 30 36 were granted an status, 14 subsequently applied at time marketing authorisation or extension indication. Most products autologous therapies using lentiviral vector developed treatment haematological B-cell malignancies. findings revealed that 80% (29/36) submissions supported preliminary data showing potential efficacy candidate added benefit currently authorised proposed condition. Notably, 89% (32/36) cases significant new was accepted clinically relevant advantage existing therapies. Twelve fourteen reviewed indication demonstrated satisfactory methods within approved therapeutic indications, but one withdrawn during evaluation. article summarises key related use primarily cancers EU. It emphasises importance supporting medical plausibility stage highlights high success rate these obtaining initial designations subsequent maintaining
Language: Английский
Citations
5
Journal of Cellular and Molecular Medicine, Journal Year: 2024, Volume and Issue: 28(9)
Published: May 1, 2024
Acute myeloid leukaemia (AML) is a fatal and refractory haematologic cancer that primarily affects adults. It interferes with bone marrow cell proliferation. Patients have 5 years survival rate of less than 30% despite the availability several treatments, including chemotherapy, allogeneic haematopoietic stem transplantation (Allo-HSCT), receptor antagonist drugs. Allo-HSCT mainstay acute treatment. Although it does work, there are severe side effects, such as graft-versus-host disease (GVHD). In recent years, chimeric antigen (CAR)-T therapies made significant progress in treatment cancer. These engineered T cells can locate recognize tumour vivo release large number effectors through immune action to effectively kill cells. CAR-T among most effective treatments because this property. demonstrated positive therapeutic results leukaemia, according numerous clinical investigations. This review highlights new targets for AML immunotherapy, limitations, difficulties therapy AML.
Language: Английский
Citations
5
Seminars in Immunopathology, Journal Year: 2024, Volume and Issue: 46(3-4)
Published: July 25, 2024
Language: Английский
Citations
4
Respiratory Medicine, Journal Year: 2025, Volume and Issue: unknown, P. 107958 - 107958
Published: Jan. 1, 2025
Language: Английский
Citations
0
Cancers, Journal Year: 2023, Volume and Issue: 15(11), P. 2944 - 2944
Published: May 27, 2023
In order to increase the effectiveness of cancer therapies and extend long-term survival patients, more often, in addition standard treatment, oncological patients receive also targeted therapy, i.e., CAR-T cells. These cells express a chimeric receptor (CAR) that specifically binds an antigen present on tumor cells, resulting cell lysis. The use therapy relapsed refractory B-type acute lymphoblastic leukemia (ALL) resulted complete remission many which prompted researchers conduct tests treatment other hematological malignancies, including myeloid (AML). AML is associated with poorer prognosis compared ALL due higher risk relapse caused by development resistance treatment. 5-year relative rate was estimated at 31.7%. objective following review mechanism action discuss latest findings results anti-CD33, -CD123, -FLT3 -CLL-1 emerging challenges as well prospects for future.
Language: Английский
Citations
10
Pharmaceuticals, Journal Year: 2025, Volume and Issue: 18(2), P. 156 - 156
Published: Jan. 24, 2025
CAR-T cell therapy has shown promising results in treating malignant hematologic diseases. The principle of this is based on the use genetically modified T lymphocytes to express a Chimeric Antigen Receptor (CAR) their membrane that specifically recognizes an antigen predominantly expressed target cells. molecular design CAR, along with advancements techniques and development “omics”, opened possibility discovering new therapeutic targets thereby expanding range diseases treated cells beyond anti-CD19 anti-BCMA for cancer. This review summarizes novel are currently used clinical trials autoimmune other challenging conditions, such as cardiac fibrosis, different infections. Additionally, challenges opportunities discussed access innovative therapy.
Language: Английский
Citations
0